Oppenheimer & Co. Inc. lifted its stake in HCA Healthcare Inc (NYSE:HCA) by 4.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,199 shares of the company’s stock after purchasing an additional 1,234 shares during the period. Oppenheimer & Co. Inc.’s holdings in HCA Healthcare were worth $2,893,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Smithfield Trust Co. raised its position in shares of HCA Healthcare by 541.9% in the 2nd quarter. Smithfield Trust Co. now owns 995 shares of the company’s stock valued at $102,000 after purchasing an additional 840 shares during the last quarter. Summit Trail Advisors LLC raised its position in HCA Healthcare by 9,933.3% during the 1st quarter. Summit Trail Advisors LLC now owns 112,774 shares of the company’s stock worth $113,000 after buying an additional 111,650 shares during the last quarter. Adviser Investments LLC purchased a new position in HCA Healthcare during the 2nd quarter worth approximately $159,000. Hyman Charles D purchased a new position in HCA Healthcare during the 2nd quarter worth approximately $205,000. Finally, Signition LP purchased a new position in HCA Healthcare during the 2nd quarter worth approximately $211,000. 70.40% of the stock is owned by institutional investors and hedge funds.
In other HCA Healthcare news, SVP Kathryn A. Torres sold 1,689 shares of the business’s stock in a transaction that occurred on Wednesday, July 25th. The stock was sold at an average price of $112.53, for a total value of $190,063.17. Following the completion of the sale, the senior vice president now owns 10,057 shares in the company, valued at $1,131,714.21. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Kathryn A. Torres sold 1,530 shares of the company’s stock in a transaction that occurred on Friday, July 27th. The stock was sold at an average price of $124.47, for a total value of $190,439.10. Following the sale, the senior vice president now owns 9,307 shares of the company’s stock, valued at approximately $1,158,442.29. The disclosure for this sale can be found here. In the last quarter, insiders sold 182,757 shares of company stock valued at $22,468,053. 2.80% of the stock is owned by company insiders.
HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Wednesday, July 25th. The company reported $2.29 EPS for the quarter, topping the Zacks’ consensus estimate of $2.16 by $0.13. The business had revenue of $11.53 billion during the quarter, compared to the consensus estimate of $11.32 billion. HCA Healthcare had a negative return on equity of 61.68% and a net margin of 6.21%. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.73 earnings per share. sell-side analysts predict that HCA Healthcare Inc will post 9.23 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 28th. Investors of record on Tuesday, September 4th will be issued a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a yield of 1.05%. The ex-dividend date is Friday, August 31st. HCA Healthcare’s dividend payout ratio (DPR) is 21.24%.
A number of brokerages have recently commented on HCA. Mizuho reaffirmed a “buy” rating and set a $145.00 price objective on shares of HCA Healthcare in a research note on Thursday, August 2nd. ValuEngine raised shares of HCA Healthcare from a “hold” rating to a “buy” rating in a research note on Wednesday, July 18th. Barclays started coverage on shares of HCA Healthcare in a research note on Tuesday, August 14th. They issued an “overweight” rating and a $150.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $135.00 target price on shares of HCA Healthcare in a research note on Thursday, July 26th. Finally, Credit Suisse Group lifted their target price on shares of HCA Healthcare from $122.00 to $143.00 and gave the stock an “outperform” rating in a research note on Friday, July 27th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and eighteen have issued a buy rating to the stock. HCA Healthcare presently has a consensus rating of “Buy” and a consensus target price of $126.33.
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Featured Article: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.